Prilenia and Ferrer begin Phase III trial of Huntington’s therapy

Prilenia Therapeutics and Ferrer have begun the confirmatory Phase III PRECISE-HD clinical trial assessing pridopidine as a ...
Healio

Measuring retinal reserve: Practical framework for functional testing, systemic biomarkers

In previous articles, I introduced retinal reserve as a framework for understanding the retina’s ability to maintain function ...

Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain, July 07, 2026--Prilenia Therapeutics B.V. and Ferreri today announced initiation of the confirmatory PRECISE-HD study (Pridopidine Phase 3 ...

Terramaster F4-425 Pro review: Excellent set-and-forget networking hardware

The TerraMaster F4-425 Pro is a compact four-bay NAS that punches above its price class, with an eight-core Intel chip, three ...

Prilenia Therapeutics B.V.: Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease

PRECISE-HD (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in Huntington's Disease (HD)) is designed to further evaluate the efficacy and safety of pridopidine, an oral investigatio ...